egnite Chosen as Finalist for Octane’s 2021 High Tech Awards

October 26, 2021

Torrey Loper

Octane’s annual High Tech Awards celebrates and recognizes individuals and companies who make Orange County a center of medical technology innovation. Throughout 28 years, the High Tech Awards have recognized more than 150 innovative companies. The annual event consists of 10 different categories ranging from Outstanding Small Technology Company to Best Technology Company Leadership Team and Best Small Technology CEO.

Octane announced the finalists for their 2021 High Tech Awards. egnite was chosen as a finalists for the “Outstanding Innovation in Medical Technology/Life Sciences” category at the 2021 High Tech Awards. This award is specifically for the innovation of a medtech/life science device or product. egnite’s CardioCare platform was nominated as the first to market solution leveraging artificial intelligence and predictive algorithms to identify the most at-risk structural heart patients to help physicians ensure patients don’t fall through the cracks.

CardioCare is making a difference by partnering with over 50 heart programs to help manage hospital’s vast structural heart patient populations and elevate the standard of patients care. Within one year of using the CardioCare platform, hospitals have observed a 29% improvement in patients diagnosed and a 35% increase in patients referred to a cardiovascular specialist.*

“We are using vast amounts of data to solve big problems and close gaps in patient care,” said Joel Portice, chief executive officer, egnite. “We believe this is the first of many AI applications that will become a game changer for our physician partners and deliver meaningful improvements in patient care, with the potential to save thousands of lives. Now, more than ever we are acting with urgency to get these AI solutions into providers’ hands.”

To learn more about CardioCare’s predictive suite, click here.

*Analysis represents aggregate median performance across 14 sites with baseline data after six months of using the CardioCare program.

#DigitalHealth #PrecisionMedicine #ArtificialIntelligenceSolutions

“These findings are extremely important and complementary to the recently presented EARLY TAVR Trial, published in the NEJM. The absence of symptoms was traditionally considered a sign of relative safety. However, this study shows how frequent acute valve syndrome is in patients undergoing AVR, and how patients would benefit greatly

Press

egnite Inc.’s Real-World Evidence Demonstrates Improved Survival in Asymptomatic Aortic Stenosis Patients Undergoing Aortic Valve Replacement (AVR)

egnite Inc.’s Real-World Evidence Demonstrates Improved Survival in Asymptomatic Aortic Stenosis Patients Undergoing Aortic Valve Replacement (AVR) Key Findings Demonstrate 3x Improved Survival for Asymptomatic AS Patients Undergoing AVR versus AS Patients Presenting with Acute Valve Syndrome ALISO VIEJO, Calif. – October 28, 2024 – egnite, Inc., a leading cardiovascular digital

Press

egnite, Inc. and JenaValve Announce Novel Research on Outcomes with Untreated Aortic Regurgitation at the 2024 American College of Cardiology Conference

egnite, Inc., a leading digital health company specializing in cardiovascular care, today announced the addition of two distinguished physicians, Vinod H. Thourani, MD and Nicholas Amoroso, MD to its Medical Advisory Board. Their wealth of expertise in cardiovascular care and dedication to innovation will significantly contribute to egnite’s mission to improve cardiovascular patient care nationwide.

egnite Chosen as Finalist for Octane’s 2021 High Tech Awards

Related Articles

Acute Valve Syndrome in Aortic Stenosis

egnite Inc.’s Real-World Evidence Demonstrates Improved Survival in Asymptomatic Aortic Stenosis Patients Undergoing Aortic Valve Replacement (AVR)

egnite, Inc. and JenaValve Announce Novel Research on Outcomes with Untreated Aortic Regurgitation at the 2024 American College of Cardiology Conference